Theorem Clinical Research

Drug Sponsors

Biota Pharmaceuticals to acquire Anaconda Pharma

Friday, February 27, 2015 02:29 PM

Biota Pharmaceuticals, based in Alpharetta, Ga., has agreed to acquire Anaconda Pharma, a privately held biotech company based in Paris.

More... »

Quest Diagnostics

Sosei acquires Heptares Therapeutics for up to $400M

Wednesday, February 25, 2015 11:36 AM

Sosei Group, a Japanese biopharmaceutical company with operations in Japan and the U.K., has acquired Heptares Therapeutics, a clinical-stage, private U.K.-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors (GPCRs).

More... »

Turing Pharmaceuticals launched

Wednesday, February 25, 2015 11:32 AM

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

More... »

Ipsen to acquire Canbex Therapeutics for $10.2M

Wednesday, February 25, 2015 11:29 AM

Canbex Therapeutics has granted Ipsen, a global specialty-driven pharmaceutical company headquartered in Paris, the exclusive right to purchase 100% of Canbex shares upon completion of the phase IIa study of Canbex’s lead candidate VSN16R for the treatment of spasticity in people with multiple sclerosis (MS).

More... »

Shire acquires Meritage Pharma

Wednesday, February 25, 2015 11:27 AM

Shire has acquired Meritage Pharma, a global, privately held company, for $70 million upfront and additional contingent payments based on development and regulatory milestones.

More... »

Baxter selects northern Illinois site for Baxalta global headquarters

Wednesday, February 25, 2015 11:25 AM

Baxalta, the biopharmaceutical company expected to separate from Baxter International in mid-year, will be headquartered in northern Illinois. A long-term lease agreement for an approximately 260,000-square-foot facility extends for more than a decade.

More... »

Valeant to acquire Salix Pharmaceuticals for $14.5B

Monday, February 23, 2015 01:11 PM

Valeant Pharmaceuticals International and Salix Pharmaceuticals, headquartered in Raleigh, N.C., have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the boards of directors of both companies. 

More... »

Sanofi appoints Olivier Brandicourt CEO

Monday, February 23, 2015 01:04 PM

Sanofi’s board of directors unanimously has appointed Olivier Brandicourt CEO.

More... »

Bristol-Myers Squibb to acquire Flexus Biosciences

Monday, February 23, 2015 01:02 PM

Bristol-Myers Squibb has signed a definitive agreement to acquire all of the outstanding capital stock of Flexus Biosciences, a San Carlos, Calif.-based, privately held biotech focused on the discovery and development of novel anti-cancer therapeutics. The transaction has a potential total consideration of $1.25 billion, including $800 million upfront and development milestones that, upon achievement, could total up to $450 million. The transaction has been approved by the boards of directors of both companies and by the stockholders of Flexus.

More... »

Actavis intends to adopt Allergan following acquisition

Thursday, February 19, 2015 02:39 PM

Actavis, headquartered in Dublin, Ireland, will adopt a new corporate name—Allergan—following the anticipated successful completion of the acquisition of Allergan. The company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis' shareholders at its annual general meeting later this year. 

More... »


March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs